Realcan Pharmaceutical Group (002589.SZ) released its performance for the first three quarters, with a net profit of 19.22 million yuan, a decrease of 68.54%.
Connect global capital markets
Realcan Pharmaceutical Group (002589.SZ) released its third quarter report for 2023. The company's operating income for the first three quarters was 6.105 billion yuan, a decrease of 43.97% compared to the same period last year. The net profit attributable to the shareholders of the listed company was 19.22 million yuan, a decrease of 68.54% compared to the same period last year. The net loss attributable to the shareholders of the listed company, excluding non-recurring gains and losses, was 105 million yuan. The basic earnings per share were 0.0128 yuan.
Related Articles
Hong Kong dollar interbank interest rates generally fell. The one-month interbank interest rate fell for three consecutive days to 2.76%.
HK Stock Market Move | Golden stocks hit the bottom and rebound, with spot gold breaking through 4700 US dollars for the first time. Institutions point out that there is still room for gold and silver to rise.
BRETON (01333) Executive Director and controlling shareholder Chen Fangming increased his holdings by 170,000 H shares.
Hong Kong dollar interbank interest rates generally fell. The one-month interbank interest rate fell for three consecutive days to 2.76%.
HK Stock Market Move | Golden stocks hit the bottom and rebound, with spot gold breaking through 4700 US dollars for the first time. Institutions point out that there is still room for gold and silver to rise.
BRETON (01333) Executive Director and controlling shareholder Chen Fangming increased his holdings by 170,000 H shares.
